May 19, 2022 Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107
May 12, 2022 Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights